JOP20210347A1 - طرق لعلاج فيروس نقص المناعة البشرية - Google Patents
طرق لعلاج فيروس نقص المناعة البشريةInfo
- Publication number
- JOP20210347A1 JOP20210347A1 JOP/2021/0347A JOP20210347A JOP20210347A1 JO P20210347 A1 JOP20210347 A1 JO P20210347A1 JO P20210347 A JOP20210347 A JO P20210347A JO P20210347 A1 JOP20210347 A1 JO P20210347A1
- Authority
- JO
- Jordan
- Prior art keywords
- rilpivirine
- methods
- pediatric patients
- treating hiv
- pediatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870413P | 2019-07-03 | 2019-07-03 | |
| US16/919,677 US20210000823A1 (en) | 2019-07-03 | 2020-07-02 | Methods of treating hiv |
| PCT/EP2020/068913 WO2021001568A1 (en) | 2019-07-03 | 2020-07-03 | Methods of treating hiv in pediatric patients with rilpivirine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210347A1 true JOP20210347A1 (ar) | 2023-01-30 |
Family
ID=71579550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0347A JOP20210347A1 (ar) | 2019-07-03 | 2021-12-30 | طرق لعلاج فيروس نقص المناعة البشرية |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20210000823A1 (enExample) |
| EP (2) | EP3993799A1 (enExample) |
| JP (4) | JP2022538338A (enExample) |
| KR (2) | KR20220028049A (enExample) |
| CN (2) | CN114126655A (enExample) |
| AU (2) | AU2020300818A1 (enExample) |
| BR (2) | BR112021026916A2 (enExample) |
| CA (1) | CA3144307A1 (enExample) |
| IL (1) | IL289457A (enExample) |
| JO (1) | JOP20210347A1 (enExample) |
| MA (2) | MA56449A (enExample) |
| MX (2) | MX2022000060A (enExample) |
| PH (1) | PH12021553288A1 (enExample) |
| WO (2) | WO2021001508A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| NZ610729A (en) * | 2010-11-19 | 2015-10-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| EP4233846B1 (en) * | 2015-06-30 | 2024-12-04 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| MA46563B1 (fr) * | 2016-10-24 | 2024-01-31 | Janssen Sciences Ireland Unlimited Co | Compositions dispersibles |
| RU2755710C2 (ru) * | 2017-06-30 | 2021-09-20 | Вайв Хелткер Компани | Комбинация, ее применение и способы лечения с использованием указанной комбинации |
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
-
2020
- 2020-07-02 MA MA056449A patent/MA56449A/fr unknown
- 2020-07-02 EP EP20739584.9A patent/EP3993799A1/en active Pending
- 2020-07-02 JP JP2021577856A patent/JP2022538338A/ja not_active Withdrawn
- 2020-07-02 MX MX2022000060A patent/MX2022000060A/es unknown
- 2020-07-02 AU AU2020300818A patent/AU2020300818A1/en not_active Abandoned
- 2020-07-02 CN CN202080048751.4A patent/CN114126655A/zh active Pending
- 2020-07-02 KR KR1020227003258A patent/KR20220028049A/ko not_active Withdrawn
- 2020-07-02 BR BR112021026916A patent/BR112021026916A2/pt unknown
- 2020-07-02 WO PCT/EP2020/068734 patent/WO2021001508A1/en not_active Ceased
- 2020-07-02 US US16/919,677 patent/US20210000823A1/en not_active Abandoned
- 2020-07-03 MX MX2021015627A patent/MX2021015627A/es unknown
- 2020-07-03 BR BR112021026739A patent/BR112021026739A2/pt unknown
- 2020-07-03 EP EP20742659.4A patent/EP3993800A1/en active Pending
- 2020-07-03 WO PCT/EP2020/068913 patent/WO2021001568A1/en not_active Ceased
- 2020-07-03 KR KR1020227003246A patent/KR20220028048A/ko not_active Withdrawn
- 2020-07-03 CN CN202080048752.9A patent/CN114080223A/zh active Pending
- 2020-07-03 JP JP2021577871A patent/JP2022538449A/ja not_active Withdrawn
- 2020-07-03 PH PH1/2021/553288A patent/PH12021553288A1/en unknown
- 2020-07-03 AU AU2020300033A patent/AU2020300033A1/en not_active Abandoned
- 2020-07-03 US US17/621,759 patent/US20220313693A1/en active Pending
- 2020-07-03 MA MA056453A patent/MA56453A/fr unknown
- 2020-07-03 CA CA3144307A patent/CA3144307A1/en active Pending
-
2021
- 2021-12-28 IL IL289457A patent/IL289457A/en unknown
- 2021-12-30 JO JOP/2021/0347A patent/JOP20210347A1/ar unknown
-
2024
- 2024-01-10 US US18/408,900 patent/US20240139186A1/en active Pending
-
2026
- 2026-02-05 JP JP2026018065A patent/JP2026097814A/ja active Pending
- 2026-02-05 JP JP2026018074A patent/JP2026097815A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021001568A1 (en) | 2021-01-07 |
| MA56449A (fr) | 2022-05-11 |
| MX2021015627A (es) | 2022-04-25 |
| CN114126655A (zh) | 2022-03-01 |
| JP2026097814A (ja) | 2026-06-16 |
| BR112021026916A2 (pt) | 2022-05-10 |
| CN114080223A (zh) | 2022-02-22 |
| CA3144307A1 (en) | 2021-01-07 |
| EP3993799A1 (en) | 2022-05-11 |
| JP2022538449A (ja) | 2022-09-02 |
| JP2022538338A (ja) | 2022-09-01 |
| MX2022000060A (es) | 2022-04-18 |
| JP2026097815A (ja) | 2026-06-16 |
| KR20220028048A (ko) | 2022-03-08 |
| US20220313693A1 (en) | 2022-10-06 |
| CA3144534A1 (en) | 2021-01-07 |
| KR20220028049A (ko) | 2022-03-08 |
| AU2020300818A1 (en) | 2022-03-03 |
| BR112021026739A2 (pt) | 2022-04-26 |
| EP3993800A1 (en) | 2022-05-11 |
| US20240139186A1 (en) | 2024-05-02 |
| PH12021553288A1 (en) | 2022-08-01 |
| US20210000823A1 (en) | 2021-01-07 |
| WO2021001508A1 (en) | 2021-01-07 |
| IL289457A (en) | 2022-02-01 |
| MA56453A (fr) | 2022-05-11 |
| AU2020300033A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125089T1 (el) | Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae | |
| EA201391108A1 (ru) | Лечение липодистрофии | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| EA202191133A1 (ru) | Сигнатуры интерферона типа i и способы их применения | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| JOP20190056B1 (ar) | مركبات للاستخدام في علاج القصور الكلوي الحاد | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| MX2017002825A (es) | Tratamientos medicos a base de anamorelina. | |
| NZ758449A (en) | Heteroaromatic compounds useful in therapy | |
| EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
| MY199237A (en) | Methods of treating ocular conditions | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| EA201792123A1 (ru) | Лечение боли | |
| EA201792056A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| EA202090558A1 (ru) | Схемы лечения | |
| EA201390925A1 (ru) | Производные санглиферина и способы их получения | |
| PH12021553288A1 (en) | Methods of treating hiv in pediatric patients with rilpivirine | |
| CO2025004675A2 (es) | Método para tratar vih con cabotegravir y rilpivirina en pacientes pediátricos | |
| MX2020000118A (es) | Composiciones y metodos para mejorar la funcion cardiaca. | |
| EA201891008A3 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| WO2016072854A3 (en) | Pantothenamide analogues | |
| EA202090452A1 (ru) | Соединения для лечения болезни фон гиппеля-линдау | |
| EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |